Prostaglandin D2 receptor Antagonist - Pipeline Insight, 2022

This “DP1 Receptor (Prostaglandin D2 receptor) Antagonist - Pipeline Insight, 2022” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in DP1 Receptor (Prostaglandin D2 receptor) Antagonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

DP1 Receptor (Prostaglandin D2 receptor) Antagonist Understanding

DP1 Receptor (Prostaglandin D2 receptor) Antagonist: Overview

Prostaglandin D2 receptor is a 395 amino acid, 43 kDa G-protein-coupled receptors. PGD2 is released following activation of the immune system, which can be either non-allergen- or allergen-dependent. Binding of PGD2 to the DP2 receptor on immune cells induces a myriad of pro-inflammatory downstream effects, which significantly contribute to the recruitment, activation and/or migration of TH2 cells, ILC2, and eosinophils. PGD2 produced by mast cells might provide an essential link between the early phase and late-phase allergic responses and such antagonism of PGD2 provides an attractive target for therapeutic intervention. Several selective, orally active, DP2 receptor antagonists are being developed for the treatment of allergic disorders.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence DP1 Receptor (Prostaglandin D2 receptor) Antagonist R&D. The therapies under development are focused on novel approaches for DP1 Receptor (Prostaglandin D2 receptor) Antagonist.

DP1 Receptor (Prostaglandin D2 receptor) Antagonist Emerging Drugs Chapters

This segment of the DP1 Receptor (Prostaglandin D2 receptor) Antagonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

DP1 Receptor (Prostaglandin D2 receptor) Antagonist Emerging Drugs

BGE-175: BioAge Labs

BGE-175 is an orally administered small-molecule based inhibitor of the prostaglandin D2 (PGD2) DP1 signaling pathway. The drug is in phase II clinical studies for the treatment of Covid-19 infections. In January 2021, Shionogi announced that it has concluded a license agreement with BioAge Labs. With this agreement, Shionogi grants BioAge exclusive U.S. and European rights to develop and commercialize BGE-175 for COVID-19 treatment. In addition, Shionogi grants BioAge exclusive rights to negotiate a license for additional indications. Under this agreement, Shionogi will receive an upfront payment and milestones according to future development, as well as royalties on sales if BGE-175 is successfully commercialized.

SLS 008: Seelos Therapeutics

SLS 008 is a small molecule, orally-bioavailable antagonist of the prostaglandin D2 receptor. The drug is in preclinical studies for the treatment of asthma, atopic dermatitis, and oesophagitis.

DP1 Receptor (Prostaglandin D2 receptor) Antagonist: Therapeutic Assessment

This segment of the report provides insights about the different DP1 Receptor (Prostaglandin D2 receptor) Antagonist drugs segregated based on following parameters that define the scope of the report.

Major Players working on DP1 Receptor (Prostaglandin D2 receptor) Antagonist

There are approx. 8+ key companies which are developing the DP1 Receptor (Prostaglandin D2 receptor) Antagonist. The companies which have their DP1 Receptor (Prostaglandin D2 receptor) Antagonist drug candidates in the most advanced stage, i.e. Phase II include, BioAge Labs.

Phases

This report covers around 8+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

DP1 Receptor (Prostaglandin D2 receptor) Antagonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

DP1 Receptor (Prostaglandin D2 receptor) Antagonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses DP1 Receptor (Prostaglandin D2 receptor) Antagonist therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging DP1 Receptor (Prostaglandin D2 receptor) Antagonist drugs.

DP1 Receptor (Prostaglandin D2 receptor) Antagonist Report Insights

• DP1 Receptor (Prostaglandin D2 receptor) Antagonist Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

DP1 Receptor (Prostaglandin D2 receptor) Antagonist Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing DP1 Receptor (Prostaglandin D2 receptor) Antagonist drugs?
• How many DP1 Receptor (Prostaglandin D2 receptor) Antagonist drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for DP1 Receptor (Prostaglandin D2 receptor) Antagonist?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the DP1 Receptor (Prostaglandin D2 receptor) Antagonist therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for DP1 Receptor (Prostaglandin D2 receptor) Antagonist and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• CSPC ZhongQi Pharmaceutical Technology
• BioAge Labs
• Novartis
• Chiesi Farmaceutici
• Idorsia Pharmaceuticals
• Seelos Therapeutics
• Sunshine Lake Pharma

Key Products

• CSPCHA-115
• Asapiprant
• Fevipiprant
• Timapiprant
• ACT-774312
• SLS 008
• Litapiprant